Bull
$14.32
Precio del escenario
$26.610
-0.189 (-0.71%)Al cierre
Pediatrix Medical Group, Inc. is a provider of physician services, including newborn, maternal-fetal, and other pediatric subspecialty care. The Company’s affiliated clinicians provide services to women, babies and children across the continuum of care, both in hospital settings and office-based practices. Its specialties include obstetrics, maternal-fetal medicine and neonatology, complemented by pediatric subspecialties. It offers specialized and critical care services through approximately 4,400 affiliated physicians and other clinicians. It provides neonatal clinical care, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications. The Company provides maternal-fetal and obstetrical medical care to expectant mothers experiencing complicated pregnancies primarily in areas where its affiliated neonatal physicians practice.
Pediatrix Medical Group Inc is currently trading at $26.61, which is close to the average analyst price target of $28. The stock has shown a strong year-to-date change of +24.99% and a 1-year change of +57.64%, indicating solid growth. However, the RSI is at 49.81, suggesting it is neither overbought nor oversold, which implies a neutral momentum. The main risk is the recent downgrade from Jefferies, which cites a more neutral risk/reward outlook after a significant price increase of 150% over the last two years, indicating potential headwinds ahead.
Jefferies
$28
2026-08-19
Jefferies
2026-08-19
Precio objetivo
$28
UBS
$28
2026-08-06
UBS
2026-08-06
Precio objetivo
$28
Deutsche Bank
$25
2026-08-05
Deutsche Bank
2026-08-05
Precio objetivo
$25
UBS
$25
2026-05-12
UBS
2026-05-12
Precio objetivo
$25
Mizuho
$24
2026-05-08
Mizuho
2026-05-08
Precio objetivo
$24
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

Pediatrix Medical Group Q2 Earnings Highlights

Surge in Options Trading Volume for Celanese and Pediatrix

Pediatrix Medical Group Q2 2026 Earnings Call Insights

Pediatrix Medical Group Reports Q2 2026 Earnings

Pediatrix Medical Group Q2 Earnings Exceed Expectations
Pediatrix Medical Group, Inc. is a provider of physician services, including newborn, maternal-fetal, and other pediatric subspecialty care. The Company’s affiliated clinicians provide services to women, babies and children across the continuum of care, both in hospital settings and office-based practices. Its specialties include obstetrics, maternal-fetal medicine and neonatology, complemented by pediatric subspecialties. It offers specialized and critical care services through approximately 4,400 affiliated physicians and other clinicians. It provides neonatal clinical care, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications. The Company provides maternal-fetal and obstetrical medical care to expectant mothers experiencing complicated pregnancies primarily in areas where its affiliated neonatal physicians practice. It operates in the Healthcare sector (SERVICES-HOSPITALS industry).
Pediatrix Medical Group Inc is currently trading at $26.61, which is close to the average analyst price target of $28. The stock has shown a strong year-to-date change of +24.99% and a 1-year change of +57.64%, indicating solid growth. However, the RSI is at 49.81, suggesting it is neither overbought nor oversold, which implies a neutral momentum. The main risk is the recent downgrade from Jefferies, which cites a more neutral risk/reward outlook after a significant price increase of 150% over the last two years, indicating potential headwinds ahead.
14 analysts cover MD: 3 rate it Buy, 10 Hold and 1 Sell. The average price target is 23.50.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.